Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-7.02%
$7.39
0% positive prob.
5-Day Prediction
-13.91%
$6.84
0% positive prob.
20-Day Prediction
-10.08%
$7.15
0% positive prob.
SEC 8-K filings with transcript text
Dec 15, 2025 · 100% conf.
1D
-7.02%
$7.39
5D
-13.91%
$6.84
20D
-10.08%
$7.15
csbr-202512150000771856false00007718562025-12-152025-12-15
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): December 15, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On December 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its second quarter ended October 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated December 15, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: December 15, 2025 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
Sep 15, 2025
csbr-202509150000771856false00007718562025-09-152025-09-15
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): September 15, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On September 15, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s unaudited financial results for its first quarter ended July 31, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated September 15, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: September 15, 2025 By:/s/ Robert Brainin Robert Brainin Chief Executive Officer
Jul 23, 2025
csbr-202507230000771856false00007718562025-07-232025-07-23
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
Date of report (Date of earliest event reported): July 23, 2025
(Exact name of registrant as specified in its charter)
Delaware 001-11504 52-1401755 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.)
1 University Plaza, Suite 307, Hackensack, New Jersey 07601 (Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (201) 808-8400
N/A (Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02.Results of Operations and Financial Condition.
On July 23, 2025, Champions Oncology, Inc. (the “Company”) issued a press release regarding the Company’s audited financial results for its fiscal year ended April 30, 2025. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information contained under Item 2.02 in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits The following exhibit is filed herewith:
Exhibit No.
99.1Press Release dated July 23, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
(Registrant)
Date: July 23, 2025By:/s/ Ronnie Morris Ronnie Morris Chief Executive Officer
This page provides Champions Oncology Inc. (CSBR) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CSBR's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.